5:18 PM
 | 
Mar 12, 2012
 |  BC Extra  |  Top Story

India grants compulsory license for Nexavar

The Indian Patent Office granted Natco Pharma Ltd. (BSE:NATCOPHAR) a compulsory license in India to manufacture and market a generic version of kidney and liver cancer drug Nexavar sorafenib. According to the order, Natco can sell the product at a price not exceeding Rs8,880 ($177) for a...

Read the full 225 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >